How to buy Acurx Pharmaceuticals stock (Acurx Pharmaceuticals)

Acurx Pharmaceuticals is a biotechnology business based in the US. Acurx Pharmaceuticals shares (ACXP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.83 – a decrease of 3.52% over the previous week. Acurx Pharmaceuticals employs 4 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Acurx Pharmaceuticals LLC stock

Buy Acurx Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Acurx Pharmaceuticals stock price (NASDAQ: ACXP)

Use our graph to track the performance of ACXP stocks over time.

Acurx Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$0.83
52-week range	$0.72 - $5.28
50-day moving average more info button	$1.57
200-day moving average more info button	$2.04
Wall St. target price	$11.19
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.09

Is it a good time to buy Acurx Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Acurx Pharmaceuticals price performance over time

Historical closes compared with the close of $0.7585 from 2024-12-19

1 week (2024-12-13)	-11.30%
1 month (2024-11-21)	-41.65%
3 months (2024-09-20)	-62.26%
6 months (2024-06-21)	-67.45%

1 year (2023-12-21)	-78.87%
2 years (2022-12-21)	-80.30%
3 years (2021-12-21)	4.5
5 years (2019-12-17)	N/A

Acurx Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-132.22%
Return on equity TTM	-346.94%
Profit margin	0%
Book value	$0.32
Market Capitalization more info button	$12.2 million

TTM: trailing 12 months

Acurx Pharmaceuticals share dividends

We're not expecting Acurx Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (6.64% forward annual dividend yield)
• Novartis AG ADR (NVS.US) (3.86% forward annual dividend yield)
• Merck-and-Company (MRK.US) (3.29% forward annual dividend yield)

Acurx Pharmaceuticals share price volatility

Over the last 12 months, Acurx Pharmaceuticals's shares have ranged in value from as little as $0.72 up to $5.28. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acurx Pharmaceuticals's is -1.722. This would suggest that Acurx Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Acurx Pharmaceuticals has bucked the trend.

To put Acurx Pharmaceuticals's beta into context you can compare it against those of similar companies.

• Pfizer (PFE.US): 0.615
• Novartis AG ADR (NVS.US): 0.505
• Merck-and-Company (MRK.US): 0.411

Acurx Pharmaceuticals overview

Acurx Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. .

Frequently asked questions

null
What percentage of Acurx Pharmaceuticals is owned by insiders or institutions?
Currently 14.802% of Acurx Pharmaceuticals shares are held by insiders and 11.964% by institutions. How many people work for Acurx Pharmaceuticals?
Latest data suggests 4 work at Acurx Pharmaceuticals. When does the fiscal year end for Acurx Pharmaceuticals?
Acurx Pharmaceuticals's fiscal year ends in December. Where is Acurx Pharmaceuticals based?
Acurx Pharmaceuticals's address is: 259 Liberty Avenue, Staten Island, NY, United States, 10305 What is Acurx Pharmaceuticals's ISIN number?
Acurx Pharmaceuticals's international securities identification number is: US00510M1045